Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs

In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with V...

Full description

Bibliographic Details
Main Authors: Marika Ruponen, Konsta Kettunen, Monica Santiago Pires, Riikka Laitinen
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/2/171
id doaj-4120191cda5b438ba6bea98db5d9a09e
record_format Article
spelling doaj-4120191cda5b438ba6bea98db5d9a09e2021-01-28T00:06:11ZengMDPI AGPharmaceutics1999-49232021-01-011317117110.3390/pharmaceutics13020171Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor DrugsMarika Ruponen0Konsta Kettunen1Monica Santiago Pires2Riikka Laitinen3School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, FinlandSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, FinlandSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, FinlandSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, FinlandIn this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with VER, PIP and QRT were prepared by solvent evaporation, and mixtures with ARG were prepared by spray drying in 1:1 and 1:2 molar ratios. The solid-state properties of the mixtures were characterized with X-ray powder diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) in stability studies under different storage conditions. Simultaneous dissolution/permeation studies were conducted in side-by-side diffusion cells with a PAMPA (parallel artificial membrane permeability assay) membrane as a permeation barrier. It was observed with XRPD that ARG, VER and PIP formed co-amorphous mixtures with FUR at both molar ratios. DSC and FTIR revealed single glass transition values for the mixtures (except for FUR:VER 1:2), with the formation of intermolecular interactions between the components, especially salt formation between FUR and ARG. The co-amorphous mixtures were found to be stable for at least two months under an elevated temperature/humidity, except FUR:ARG 1:2, which was sensitive to humidity. The dissolution/permeation studies showed that only the co-amorphous FUR:ARG mixtures were able to enhance both the dissolution and permeation of FUR. Thus, it is concluded that formulating co-amorphous salts with ARG may be a promising option for poorly soluble/permeable FUR.https://www.mdpi.com/1999-4923/13/2/171co-amorphousdissolutionsolubilitystabilitypermeationP-gp inhibitor
collection DOAJ
language English
format Article
sources DOAJ
author Marika Ruponen
Konsta Kettunen
Monica Santiago Pires
Riikka Laitinen
spellingShingle Marika Ruponen
Konsta Kettunen
Monica Santiago Pires
Riikka Laitinen
Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
Pharmaceutics
co-amorphous
dissolution
solubility
stability
permeation
P-gp inhibitor
author_facet Marika Ruponen
Konsta Kettunen
Monica Santiago Pires
Riikka Laitinen
author_sort Marika Ruponen
title Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
title_short Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
title_full Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
title_fullStr Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
title_full_unstemmed Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
title_sort co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2021-01-01
description In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with VER, PIP and QRT were prepared by solvent evaporation, and mixtures with ARG were prepared by spray drying in 1:1 and 1:2 molar ratios. The solid-state properties of the mixtures were characterized with X-ray powder diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) in stability studies under different storage conditions. Simultaneous dissolution/permeation studies were conducted in side-by-side diffusion cells with a PAMPA (parallel artificial membrane permeability assay) membrane as a permeation barrier. It was observed with XRPD that ARG, VER and PIP formed co-amorphous mixtures with FUR at both molar ratios. DSC and FTIR revealed single glass transition values for the mixtures (except for FUR:VER 1:2), with the formation of intermolecular interactions between the components, especially salt formation between FUR and ARG. The co-amorphous mixtures were found to be stable for at least two months under an elevated temperature/humidity, except FUR:ARG 1:2, which was sensitive to humidity. The dissolution/permeation studies showed that only the co-amorphous FUR:ARG mixtures were able to enhance both the dissolution and permeation of FUR. Thus, it is concluded that formulating co-amorphous salts with ARG may be a promising option for poorly soluble/permeable FUR.
topic co-amorphous
dissolution
solubility
stability
permeation
P-gp inhibitor
url https://www.mdpi.com/1999-4923/13/2/171
work_keys_str_mv AT marikaruponen coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs
AT konstakettunen coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs
AT monicasantiagopires coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs
AT riikkalaitinen coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs
_version_ 1724320199702740992